Lilly's Zepbound Boosts Taltz Response in Psoriasis Study
Lilly reports Zepbound (tirzepatide) enhanced Taltz (ixekizumab) efficacy in a psoriasis study, a signal for combination therapy in metabolic-psoriatic disease.
Stories
Daniel Okafor
Stories
Daniel Okafor
Palvella Puts U.S. DSAP Population at 154,986 in New Posters
Palvella Therapeutics posters estimate 154,986 U.S. patients with disseminated superficial actinic porokeratosis, sharpening the…
Enfortumab Vedotin Reactions Reclassified as TEC, Not TEN
A JAAD analysis published October 12, 2026 reclassifies severe enfortumab vedotin cutaneous reactions as TEC rather than TEN, wit…
PDRN in Topical Skin Care: What the Evidence Actually Supports
A review of 50+ PDRN products found marine, recombinant, bacterial, microalgae and plant sources sharing one label — none biologi…
Lilly Reports Taltz-Zepbound Combo Beats Taltz Alone in Psoriasis Study
Eli Lilly says a psoriasis study found Taltz plus Zepbound outperformed Taltz monotherapy; full efficacy and safety data are stil…
Icotrokinra Sustains Psoriasis Skin Clearance Through 2 Years
Two-year ICONIC-LEAD data show oral IL-23 receptor antagonist icotrokinra sustained skin clearance in plaque psoriasis, strengthe…
Liver Function Test Elevations Rare With Biologics in Psoriasis and HS
Liver function test elevations occur rarely in psoriasis and HS patients on biologics, Dermatology Times reports — supporting str…
Attention-Guided Fair AI Modeling for Skin Cancer Diagnosis Published in Nature
A Nature publication introduces attention-guided fair artificial intelligence modeling for skin cancer diagnosis, aiming to reduc…
FDA Approves Priteliver for Refractory Herpes Infections
The US FDA has approved pritelivir for refractory herpes infections, giving dermatologists a new option for patients who fail sta…
New Consensus Statement Defines Remission, Disease Activity in Atopic Dermatitis
A newly published consensus standardizes definitions of remission and disease activity in atopic dermatitis, aligning trial endpo…